Durect Corp. Stock
Your prediction
Durect Corp. Stock
Our community identified positive and negative aspects for Durect Corp. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Durect Corp. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Durect Corp. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Durect Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Durect Corp. | - | - | - | - | - | - | - |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -1.610% | -0.093% | 14.255% | -72.306% | -61.293% | -71.444% | -95.712% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for DRRX provided by MarketBeat
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for DRRX provided by MarketBeat
DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for DRRX provided by MarketBeat
News
Bausch Health Cos Q2 Earnings Call Highlights
Key Points
- Interested in Bausch Health Cos Inc.? Here are five stocks we like better.
- Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch +
